Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: May 11, 2024
Date Accepted: Jan 31, 2025

The final, peer-reviewed published version of this preprint can be found here:

Prediction of Reactivation After Antivascular Endothelial Growth Factor Monotherapy for Retinopathy of Prematurity: Multimodal Machine Learning Model Study

Wu R, Zhang Y, Huang P, Xie Y, Wang J, Wang S, Lin Q, Bai Y, Feng S, Cai N, Lu X

Prediction of Reactivation After Antivascular Endothelial Growth Factor Monotherapy for Retinopathy of Prematurity: Multimodal Machine Learning Model Study

J Med Internet Res 2025;27:e60367

DOI: 10.2196/60367

PMID: 40267476

PMCID: 12063557

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Prediction of Reactivation after Anti-VEGF Monotherapy for Retinopathy of Prematurity Using Multimodal Machine Learning models

  • Rong Wu; 
  • Yu Zhang; 
  • Peijie Huang; 
  • Yiling Xie; 
  • Jianxun Wang; 
  • Shuangyong Wang; 
  • Qiuxia Lin; 
  • Yichen Bai; 
  • Songfu Feng; 
  • Nian Cai; 
  • Xiaohe Lu

ABSTRACT

Background:

Retinopathy pf prematurity is the leading preventable cause of childhood blind-ness, timely intravitreal injection of anti-vascular endothelial growth factor is re-quired to prevent retinal detachment with consequent vision impairment and loss. However, anti- vascular endothelial growth factor has been reported to be associated with ROP reactivation. Therefore, prediction of reactivation after treatment is urgent need.

Objective:

To develop and validate prediction models for reactivation after anti-vascular endothelial growth factor intravitreal injection in infants with retinopathy of prema-turity using multimodal machine learning algorithms.

Methods:

Infants with ROP undergoing anti-vascular endothelial growth factor treatment were recruited from three hospitals, conventional machine learning, deep learning and fusion models were constructed. The areas under the curve, accurancy, sensitivity and specificity were used to show the performances of the prediction models.

Results:

239 cases with anti-vascular endothelial growth factor treatment were recruit-ed, including 90 with reactivation and 149 non-reactivation cases. The area under the curve for the conventional machine learning model was 0.806 and 0.805 in the inter-nal and external validation groups, respectively. The average area under the curve, sensitivity, and specificity in the external validation for the deep learning model were 0.787, 0.800 and 0.570, respectively. The specificity, area under the curve, and sensitivity for the fusion model were 0.686, 0.822, and 0.800 in external validation, separately.

Conclusions:

We constructed three prediction models for the reactivation of retinopathy of prematurity, fusion model achieved the best performance. Using this prediction model, we may optimize strategies for treating retinopathy of prematurity infants and developing better screening plans after treatment.


 Citation

Please cite as:

Wu R, Zhang Y, Huang P, Xie Y, Wang J, Wang S, Lin Q, Bai Y, Feng S, Cai N, Lu X

Prediction of Reactivation After Antivascular Endothelial Growth Factor Monotherapy for Retinopathy of Prematurity: Multimodal Machine Learning Model Study

J Med Internet Res 2025;27:e60367

DOI: 10.2196/60367

PMID: 40267476

PMCID: 12063557

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.